|
US9732131B2
(en)
|
2006-02-27 |
2017-08-15 |
Calviri, Inc. |
Identification and use of novopeptides for the treatment of cancer
|
|
KR20170080697A
(ko)
|
2014-11-13 |
2017-07-10 |
더 존스 홉킨스 유니버시티 |
관문 차단 및 미소부수체 불안정성
|
|
MA40737A
(fr)
*
|
2014-11-21 |
2017-07-04 |
Memorial Sloan Kettering Cancer Center |
Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
|
|
WO2016146143A1
(en)
|
2015-03-16 |
2016-09-22 |
Amal Therapeutics Sa |
Cell penetrating peptides and complexes comprising the same
|
|
US20190099475A1
(en)
|
2015-04-08 |
2019-04-04 |
Nantomics, Llc |
Cancer neoepitopes
|
|
CA3172682A1
(en)
*
|
2015-04-23 |
2016-10-27 |
Nantomics, Llc |
Cancer neoepitopes
|
|
EP3294324A1
(en)
|
2015-05-13 |
2018-03-21 |
Agenus Inc. |
Vaccines for treatment and prevention of cancer
|
|
GB201516047D0
(en)
*
|
2015-09-10 |
2015-10-28 |
Cancer Rec Tech Ltd |
Method
|
|
AU2016339035A1
(en)
*
|
2015-10-12 |
2018-05-10 |
Nantomics, Llc |
Systems, compositions, and methods for discovery of MSI and neoepitopes that predict sensitivity to checkpoint inhibitors
|
|
WO2017066290A1
(en)
*
|
2015-10-12 |
2017-04-20 |
Nantomics, Llc |
Viral neoepitopes and uses thereof
|
|
CN108601820A
(zh)
*
|
2015-10-12 |
2018-09-28 |
南托米克斯有限责任公司 |
用于病毒癌症新表位的组合物和方法
|
|
JP6938489B2
(ja)
*
|
2015-10-23 |
2021-09-22 |
ノバルティス・エイジーＮｏｖａｒｔｉｓ ＡＧ |
視野に存在する選択された細胞のバイオマーカー陽性率の値を導き出す方法
|
|
TWI733719B
(zh)
|
2015-12-07 |
2021-07-21 |
美商河谷控股Ｉｐ有限責任公司 |
改善的組合物及用於新表位之病毒遞送的方法及其應用
|
|
JP7114477B2
(ja)
|
2015-12-16 |
2022-08-08 |
グリットストーン バイオ インコーポレイテッド |
新生抗原の特定、製造、および使用
|
|
WO2017118702A1
(en)
*
|
2016-01-08 |
2017-07-13 |
Vaccibody As |
Neoepitope rna cancer vaccine
|
|
AU2017219901B2
(en)
|
2016-02-19 |
2022-07-14 |
Nant Holdings Ip, Llc |
Methods of immunogenic modulation
|
|
US11725247B2
(en)
|
2016-02-29 |
2023-08-15 |
Foundation Medicine, Inc. |
Methods of treating cancer
|
|
WO2017151502A1
(en)
|
2016-02-29 |
2017-09-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
JP6710004B2
(ja)
*
|
2016-03-15 |
2020-06-17 |
Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 |
免疫療法のためのモニタリングまたは診断ならびに治療剤の設計
|
|
EP3429618B1
(en)
*
|
2016-03-16 |
2024-02-21 |
Amal Therapeutics SA |
Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
|
|
CA3026563C
(en)
*
|
2016-06-10 |
2023-11-28 |
Io Therapeutics, Inc. |
Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
|
|
US20190247435A1
(en)
*
|
2016-06-29 |
2019-08-15 |
The Johns Hopkins University |
Neoantigens as targets for immunotherapy
|
|
KR20190057345A
(ko)
|
2016-09-21 |
2019-05-28 |
아말 테라퓨틱스 에스에이 |
암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
|
|
US11332530B2
(en)
|
2016-09-23 |
2022-05-17 |
Memorial Sloan Kettering Cancer Center |
Determinants of cancer response to immunotherapy
|
|
KR102804118B1
(ko)
*
|
2016-10-06 |
2025-05-09 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
WO2018102613A2
(en)
|
2016-12-01 |
2018-06-07 |
Nantomics, Llc |
Tumor antigenicity processing and presentation
|
|
WO2018112449A2
(en)
|
2016-12-16 |
2018-06-21 |
Nant Holdings Ip, Llc |
Live cell imaging systems and methods to validate triggering of immune response
|
|
WO2018132753A1
(en)
*
|
2017-01-13 |
2018-07-19 |
Nantbio, Inc. |
Validation of neoepitope-based treatment
|
|
US12331359B2
(en)
|
2017-01-18 |
2025-06-17 |
Michael Laessig |
Neoantigens and uses thereof for treating cancer
|
|
WO2018146128A1
(en)
*
|
2017-02-07 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
|
|
AU2018234821A1
(en)
*
|
2017-03-17 |
2019-09-26 |
Nantomics, Llc |
Liquid biopsy for cfRNA
|
|
EP3601355A1
(en)
*
|
2017-03-31 |
2020-02-05 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
WO2018222433A2
(en)
|
2017-05-30 |
2018-12-06 |
Nant Holdings Ip, Llc |
Circulating tumor cell enrichment using neoepitopes
|
|
EP3630131B1
(en)
|
2017-06-02 |
2022-08-31 |
Arizona Board of Regents on behalf of Arizona State University |
A method to create personalized canine cancer vaccines
|
|
CN111033631B
(zh)
*
|
2017-06-13 |
2024-03-12 |
波士顿基因公司 |
用于生成分子功能谱、对其进行可视化和分类的系统和方法
|
|
GB201710815D0
(en)
*
|
2017-07-05 |
2017-08-16 |
Francis Crick Inst Ltd |
Method
|
|
US12025615B2
(en)
|
2017-09-15 |
2024-07-02 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods of classifying response to immunotherapy for cancer
|
|
KR20200059243A
(ko)
|
2017-09-20 |
2020-05-28 |
리제너론 파마슈티칼스 인코포레이티드 |
패신저 유전자 돌연변이 부담이 높은 종양을 가진 환자에 대한 면역 치료요법
|
|
EP3688165A4
(en)
|
2017-09-25 |
2021-09-29 |
Nant Holdings IP, LLC |
VALIDATION OF THE PRESENTATION OF NEOEPITOPES
|
|
AU2018338441B2
(en)
*
|
2017-09-25 |
2025-08-14 |
Memorial Sloan Kettering Cancer Center |
Tumor mutational load and checkpoint immunotherapy
|
|
CN111465989B
(zh)
|
2017-10-10 |
2024-06-25 |
磨石生物公司 |
使用热点进行的新抗原鉴别
|
|
EP3694884A1
(en)
|
2017-10-15 |
2020-08-19 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
EP3704268B1
(en)
|
2017-11-03 |
2025-01-22 |
Guardant Health, Inc. |
Normalizing tumor mutation burden
|
|
CN111566484A
(zh)
*
|
2017-11-09 |
2020-08-21 |
宾夕法尼亚大学董事会 |
细胞外囊泡蛋白及其在癌症诊断、预测对疗法的反应和治疗中的用途
|
|
AU2018373154B2
(en)
|
2017-11-22 |
2025-08-07 |
Seattle Project Corp. |
Reducing junction epitope presentation for neoantigens
|
|
EP3622522A1
(en)
|
2017-12-01 |
2020-03-18 |
Illumina, Inc. |
Methods and systems for determining somatic mutation clonality
|
|
CN108009400B
(zh)
*
|
2018-01-11 |
2018-07-06 |
至本医疗科技（上海）有限公司 |
全基因组肿瘤突变负荷预测方法、设备以及存储介质
|
|
US11414698B2
(en)
*
|
2018-03-22 |
2022-08-16 |
Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi |
Method of quantifying mutant allele burden of target gene
|
|
EP3784688A2
(en)
|
2018-04-26 |
2021-03-03 |
Agenus Inc. |
Heat shock protein-binding peptide compositions and methods of use thereof
|
|
CN120193081A
(zh)
|
2018-07-23 |
2025-06-24 |
夸登特健康公司 |
用于通过肿瘤分数和覆盖率调整肿瘤突变负荷的方法和系统
|
|
JP7539367B2
(ja)
|
2018-08-31 |
2024-08-23 |
ガーダント ヘルス， インコーポレイテッド |
無細胞ｄｎａにおけるマイクロサテライト不安定性の検出
|
|
CN109371005B
(zh)
*
|
2018-11-12 |
2022-09-30 |
上海市东方医院（同济大学附属东方医院） |
一种hla-0201限制性padi4表位多肽及其应用
|
|
WO2020121226A1
(en)
*
|
2018-12-12 |
2020-06-18 |
Medimmune, Llc |
Blood-based tumor mutation burden predicts overall survival in non-small cell lung cancer
|
|
KR20210148077A
(ko)
|
2018-12-21 |
2021-12-07 |
에이전시 포 사이언스, 테크놀로지 앤드 리서치 |
면역 체크포인트 억제 요법으로부터의 수혜를 예측하는 방법
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
EP3947739A1
(en)
*
|
2019-04-05 |
2022-02-09 |
Illumina, Inc. |
Quantitative score of hla diversity
|
|
EP3977136A4
(en)
*
|
2019-05-24 |
2023-05-10 |
Edifice Health, Inc. |
PRECISION DRUGS FOR CANCER IMMUNOTHERAPY
|
|
EP4038222A4
(en)
|
2019-10-02 |
2023-10-18 |
Arizona Board of Regents on behalf of Arizona State University |
Methods and compositions for identifying neoantigens for use in treating and preventing cancer
|
|
NL2024107B1
(en)
*
|
2019-10-26 |
2021-07-19 |
Vitroscan B V |
Compositions for Patient Specific Immunotherapy
|
|
CN111088349B
(zh)
*
|
2020-02-14 |
2023-04-28 |
深圳市宝安区妇幼保健院 |
Kir3dl1基因分型引物组及其应用
|
|
EP4127243B1
(en)
*
|
2020-03-23 |
2023-11-22 |
Koninklijke Philips N.V. |
Prediction of radiotherapy response for prostate cancer subject based on immune checkpoint genes
|
|
GB202007099D0
(en)
|
2020-05-14 |
2020-07-01 |
Kymab Ltd |
Tumour biomarkers for immunotherapy
|
|
WO2022009049A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
EP4175664A2
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
EP4000595A1
(en)
*
|
2020-11-17 |
2022-05-25 |
The Boots Company plc |
Tetrapeptide and compositions comprising tetrapeptides
|
|
EP4000596A1
(en)
*
|
2020-11-17 |
2022-05-25 |
The Boots Company plc |
Tetrapeptide and compositions comprising tetrapeptides
|
|
US20240192195A1
(en)
*
|
2021-04-10 |
2024-06-13 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
A multiomic approach to modeling of gene regulatory networks in multiple myeloma
|
|
AU2021461416A1
(en)
|
2021-08-24 |
2024-02-22 |
BioNTech SE |
In vitro transcription technologies
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
CN122003713A
(zh)
|
2023-04-12 |
2026-05-08 |
西奈山伊坎医学院 |
用于选择个性化新抗原疫苗的计算方法
|